875258-85-8Relevant academic research and scientific papers
GHSR1A ANTAGONIST FOR PRADER-WILLI SYNDROME TREATMENT
-
Page/Page column 10; 11, (2019/06/11)
We have developed of Class B GHSR1a antagonists useful for the treatment of the genetic disease Prader-Willi syndrome, which is associated with Type 2 diabetes and obesity. Compounds that can be used in the practice of the invention include SR16281 and YIL781.
Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity
Rudolph, Joachim,Esler, William P.,O'Connor, Stephen,Coish, Philip D. G.,Wickens, Philip L.,Brands, Michael,Bierer, Donald E.,Bloomquist, Brian T.,Bondar, Georgiy,Chen, Libing,Chuang, Chih-Yuan,Claus, Thomas H.,Fathi, Zahra,Fu, Wenlang,Khire, Uday R.,Kristie, James A.,Liu, Xiao-Gao,Lowe, Derek B.,McClure, Andrea C.,Michels, Martin,Ortiz, Astrid A.,Ramsden, Philip D.,Schoenleber, Robert W.,Shelekhin, Tatiana E.,Vakalopoulos, Alexandras,Tang, Weifeng,Wang, Lei,Yi, Lin,Gardell, Stephen J.,Livingston, James N.,Sweet, Laurel J.,Bullock, William H.
, p. 5202 - 5216 (2008/03/12)
The peptide hormone ghrelin is the endogenous ligand for the type 1a growth hormone secretagogue receptor (GHS-R1a) and the only currently known circulating appetite stimulant. GHS-R1a antagonism has therefore been proposed as a potential approach for obe
QUINAZOLINONE DERIVATIVES USEFUL FOR THE REGULATION OF GLUCOSE HOMEOSTASIS AND FOOD INTAKE
-
Page/Page column 163, (2010/10/19)
This invention relates to substituted quinazolinone derivatives, compositions, and methods for treating diabetes, obesity and related disorders, and regulation of food intake (e.g., stimulation and suppression).
